Tarsus Pharmaceuticals, Inc. Net Income Loss

Quick Answer

Tarsus Pharmaceuticals, Inc. reported Net Income Loss of -$66.42 million for the year ending 2025.

  • Tarsus Pharmaceuticals, Inc. showed an increase of +42.5% in Net Income Loss from 2024 to 2025.
  • This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
  • XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 8 years of available data (2018 to 2025), Tarsus Pharmaceuticals, Inc.'s Net Income Loss has declined by 4,935.5%.
  • Historical annual values: Fiscal year 2025: -$66.42 million | Fiscal year 2024: -$115.55 million | Fiscal year 2023: -$135.89 million | Fiscal year 2022: -$62.09 million | Fiscal year 2021: -$13.83 million | Fiscal year 2020: -$26.81 million | Fiscal year 2019: -$4.67 million | Fiscal year 2018: -$1.32 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: